Abstract
Inflammatory bowel disease (IBD) is a group of disorders characterized by chronic inflammation within the gastrointestinal tract. It is a multifactorial disease associated with immune-cell mediated oxidative damage to the intestinal mucosa. There is no cure for IBD, but anti-cytokine therapy can limit target inflammation and disease progression. Unfortunately, many patients are nonresponsive or develop resistance to anti-cytokine therapy over time creating a need for new therapeutic agents. Metallothionein (MT) is a small, highly conserved stress response protein that has been shown to modulate the immune response as a pro-inflammatory agent, regulates divalent heavy metal homeostasis, and acts as a reactive metabolite scavenger. Our research, as well as other groups studying MT, has described MT induction and release during IBD inflammatory stress response. The release of MT results in activation of inflammatory responses leading to progressive inflammation and subsequent expansion of MT synthesis. A monoclonal antibody specific for MT has been used in murine models of IBD and should only target the extracellular pool of MT, thus representing a novel therapeutic approach to this disease.
Keywords: Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Metallothionein, biologic therapy, inflammation.
Current Pharmaceutical Design
Title:Metallothionein: A Novel Therapeutic Target for Treatment of Inflammatory Bowel Disease
Volume: 24 Issue: 27
Author(s): Kristen E. Dostie, Amy V. Thees and Michael A. Lynes*
Affiliation:
- Department of Molecular and Cell Biology, University of Connecticut, Storrs,United States
Keywords: Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Metallothionein, biologic therapy, inflammation.
Abstract: Inflammatory bowel disease (IBD) is a group of disorders characterized by chronic inflammation within the gastrointestinal tract. It is a multifactorial disease associated with immune-cell mediated oxidative damage to the intestinal mucosa. There is no cure for IBD, but anti-cytokine therapy can limit target inflammation and disease progression. Unfortunately, many patients are nonresponsive or develop resistance to anti-cytokine therapy over time creating a need for new therapeutic agents. Metallothionein (MT) is a small, highly conserved stress response protein that has been shown to modulate the immune response as a pro-inflammatory agent, regulates divalent heavy metal homeostasis, and acts as a reactive metabolite scavenger. Our research, as well as other groups studying MT, has described MT induction and release during IBD inflammatory stress response. The release of MT results in activation of inflammatory responses leading to progressive inflammation and subsequent expansion of MT synthesis. A monoclonal antibody specific for MT has been used in murine models of IBD and should only target the extracellular pool of MT, thus representing a novel therapeutic approach to this disease.
Export Options
About this article
Cite this article as:
Dostie E. Kristen , Thees V. Amy and Lynes A. Michael *, Metallothionein: A Novel Therapeutic Target for Treatment of Inflammatory Bowel Disease, Current Pharmaceutical Design 2018; 24 (27) . https://dx.doi.org/10.2174/1381612824666180717110236
DOI https://dx.doi.org/10.2174/1381612824666180717110236 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Directing an Appropriate Immune Response: The Role of Defense Collagens and other Soluble Pattern Recognition Molecules
Current Drug Targets Targeting the Human Thioredoxin System by Diverse Strategies to Treat Cancer and Other Pathologies
Recent Patents on DNA & Gene Sequences Podocytes as a Target of Insulin
Current Diabetes Reviews Mesalamine for Inflammatory Bowel Disease: Recent Reappraisals
Inflammation & Allergy - Drug Targets (Discontinued) Understanding Respiratory Syncytial Virus Infection to Improve Treatment and Immunity
Current Molecular Medicine Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
Current Neuropharmacology Hesperetin Mitigates Bile Duct Ligation-Induced Liver Fibrosis by Inhibiting Extracellular Matrix and Cell Apoptosis via the TGF-β1/Smad Pathway
Current Molecular Medicine Exercise and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets A Novel Approach to Label-Free Sensing: Diffractive Optics Technology (dot®)
Combinatorial Chemistry & High Throughput Screening Engineering of Therapeutic Proteins Production in Escherichia coli
Current Pharmaceutical Biotechnology Current Perspectives on the Therapeutic Utility of VR1 Antagonists
Current Medicinal Chemistry Postpartum Haemorrhage, A Persisting Killer Around the Globe, Road Ahead
Current Women`s Health Reviews Role of CD14 in Host Response to Infection
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Small Amine Molecules: Solvent Design Toward Facile Improvement of Protein Stability Against Aggregation and Inactivation
Current Pharmaceutical Biotechnology New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Involvement of Breast Cancer-Associated Fibroblasts in Tumor Development, Therapy Resistance and Evaluation of Potential Therapeutic Strategies
Current Medicinal Chemistry Nitric Oxide and its Role in Ischaemic Brain Injury
Current Molecular Medicine Impact of Sphingosine Kinase on Inflammatory Pathways in Fibroblast-Like Synoviocytes
Inflammation & Allergy - Drug Targets (Discontinued) Strategies to Design Inhibitors of Clostridium Botulinum Neurotoxins
Infectious Disorders - Drug Targets Chemical Aspects of Coumarin Compounds for the Prevention of Hepatocellular Carcinomas
Current Medicinal Chemistry - Anti-Cancer Agents